Jonathan I. Silverberg
Hautarzt,
Arzt
Hat mitgewirkt an:
-
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
-
Impact of Ruxolitinib Cream on Work Productivity and Activity Impairment and Associated Indirect Costs in Patients with Atopic Dermatitis: Pooled Results From Two Phase III Studies
-
Real‐world clinical, psychosocial and economic burden of atopic dermatitis: results from a multicountry study
-
Financial burden and impact of atopic dermatitis out-of-pocket healthcare expenses among black individuals in the United States